# SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

# **SCHEDULE 13G** (Rule 13d-102)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)

(Amendment No. )<sup>1</sup>

(Name of Issuer)		
(Title of Class of Securities)		
338488109		
(CUSIP Number)		
November 13, 2007		
(Date of Event Which Requires Filing of this Statement)		
designate the rule pursuant to which this Schedule is filed:		

Check the appropriate box to

o Rule 13d-1(b)

⊠ Rule 13d-1(c)

o Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. 338488109		13G	Page 2 of 10 Pages
1	NAME OF REPORTIN Biotechnology Value F I.R.S. IDENTIFICATIO		
2	CHECK THE APPROP	PRIATE BOX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o
3	SEC USE ONLY		
4	CITIZENSHIP OR PLA	ACE OF ORGANIZATION	
9	384,157	5 SOLE VOTING POWER  6 SHARED VOTING POWER  384,157  7 SOLE DISPOSITIVE POWER  0  8 SHARED DISPOSITIVE POWER  384,157  JNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	CHECK IF THE AGO	GREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
11	PERCENT OF CLAS	S REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORTIN	IG PERSON*	
	PN		

		_	
CUSIP No. 338488109		13G	Page 3 of 10 Pages
1	NAME OF REPORTIN Biotechnology Value I I.R.S. IDENTIFICATIO		
2	CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o
3	SEC USE ONLY		
4	CITIZENSHIP OR PL	ACE OF ORGANIZATION	
	NUMBER OF SHARES ENEFICIALLY OWNED BY EACH	5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 298,370 7 SOLE DISPOSITIVE POWER	
1	REPORTING PERSON WITH:	8 SHARED DISPOSITIVE POWER 298,370	
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10	CHECK IF THE AGO	GREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  1.2%		
12	TYPE OF REPORTI	NG PERSON*	
	PN		

CUSIP No. 3	338488109	13G	Page 4 of 10 Pages
BVF I	OF REPORTING PERSO nvestments, L.L.C. IDENTIFICATION NOS. O	N: DF ABOVE PERSONS (ENTITIES ONLY):	
2 CHEC	K THE APPROPRIATE BO	OX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o
3 SEC U	SE ONLY		
4 CITIZI	ENSHIP OR PLACE OF O	RGANIZATION	
NUMBEI SHARI BENEFICI OWNE BY EACI REPORT PERSO	ES 6 EALLY 6 ED 7 TING DN —	SOLE VOTING POWER  0  SHARED VOTING POWER  962,400  SOLE DISPOSITIVE POWER  0	
9 AGG	REGATE AMOUNT BEN	SHARED DISPOSITIVE POWER 962,400  EFICIALLY OWNED BY EACH REPORTING PERSON	
		AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
11 PERC 4.0%		SENTED BY AMOUNT IN ROW (9)	
<b>12</b> TYPE	E OF REPORTING PERSO	)N*	
00			

CUSIP No. 3384881	9 13G	Page 5 of 10 Pages
Investments 10	PORTING PERSON: , L.L.C. ICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):	
2 CHECK THE A	PPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o
3 SEC USE ONL	Y	
4 CITIZENSHIP  Illinois	OR PLACE OF ORGANIZATION	
NUMBER OF SHARES	5 SOLE VOTING POWER 0	
BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 110,720	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 110,720	
9 AGGREGAT	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10 CHECK IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
11 PERCENT O	CLASS REPRESENTED BY AMOUNT IN ROW (9)	
0.5%		
12 TYPE OF RE	PORTING PERSON*	
00		

CUSIP No.	338488109	13G	Page 6 of 10 Pages
BVF	E OF REPORTING PERSO Partners L.P. IDENTIFICATION NOS.	ON: OF ABOVE PERSONS (ENTITIES ONLY):	
2 CHEC	CK THE APPROPRIATE B	OX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o
3 SEC	USE ONLY		
4 CITIZ	ZENSHIP OR PLACE OF C	PRGANIZATION	
	RES CIALLY 6 FED 7 TING FON H: 8	SOLE VOTING POWER  SHARED VOTING POWER  1,755,647  SOLE DISPOSITIVE POWER  O  SHARED DISPOSITIVE POWER  1,755,647  EFICIALLY OWNED BY EACH REPORTING PERSON	
		AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
11 PER		SENTED BY AMOUNT IN ROW (9)	
12 TYF	PE OF REPORTING PERSO	DN*	
PN			

CUSIP No. 338488109		13G	Page 7 of 10 Pages
В	IAME OF REPORTIN VF Inc. .S. OR I.R.S. IDENTI	G PERSON: FICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):	
<b>2</b> C	HECK THE APPROP	RIATE BOX IF A MEMBER OF A GROUP*	(a) ⊠ (b) o
3 S	EC USE ONLY		
	EITIZENSHIP OR PLA	CE OF ORGANIZATION	
S BENI C REI P	MBER OF HARES EFICIALLY DWNED BY EACH PORTING ERSON WITH:	5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 1,755,647  7 SOLE DISPOSITIVE POWER 0  8 SHARED DISPOSITIVE POWER 1,755,647	
	1,755,647	INT BENEFICIALLY OWNED BY EACH REPORTING PERSON  REGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	0
	PERCENT OF CLASS	S REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORTIN	G PERSON*	
	IA, CO		

## ITEM 1(a). NAME OF ISSUER:

Flamel Technologies, S.A. ("Flamel")

## ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

Parc Club Du Moulin A Vent 33 Avenue Du Docteur Georges Levy 69693 Venissieux Cedex France

#### ITEM 2(a). NAME OF PERSON FILING:

This Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

- (i) Biotechnology Value Fund, L.P. ("BVF")
- (ii) Biotechnology Value Fund II, L.P. ("BVF2")
- (iii) BVF Investments, L.L.C. ("Investments")
- (iv) Investment 10, L.L.C. ("ILL10")
- (v) BVF Partners L.P. ("Partners")
- (vi) BVF Inc. ("BVF Inc.")

## ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

The principal business office of the Reporting Persons comprising the group filing this Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.

## ITEM 2(c). CITIZENSHIP:

BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Investments: a Delaware limited liability company
ILL10: an Illinois limited liability company
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation

# ITEM 2(d). TITLE OF CLASS OF SECURITIES:

This Schedule 13G is being filed with respect to the French Ordinary Shares represented by American Depositary Shares ("Ordinary Shares") of Flamel. The Reporting Persons' percentage ownership of Ordinary Shares is based on 24,041,590 Ordinary Shares being outstanding.

As of November 20, 2007, (i) BVF beneficiary owned 384,157 Ordinary Shares; (ii) BVF2 beneficially owned 298,370 Ordinary Shares; (iii) Investments beneficially owned 962,400 Ordinary Shares; and (iv) ILL10 beneficially owned 110,720 Ordinary Shares. Beneficial ownership by Partners and BVF Inc. includes 1,755,647 Ordinary Shares.

# ITEM 2(e). CUSIP Number:

338488109

CUSIP No. 338488109	40.0	Dage 0 of 10 Dages
CUSIP No. 330400109	13G	Page 9 of 10 Pages

# ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS: One of the following

Not applicable as this Schedule 13G is filed pursuant to Rule 13d-1(c).

## ITEM 4. OWNERSHIP:

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Schedule 13G is hereby incorporated by reference.

## ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following. o

## ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Ziff Asset Management, L.P., the majority member of Investments, in shares of the Common Stock beneficially owned by Investments and to vote and exercise dispositive power over those shares of the Common Stock. Partners and BVF Inc. share voting and dispositive power over shares of the Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as an investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of the Common Stock owned by such parties.

# ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:

Not applicable.

#### ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:

Not applicable.

#### ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

Not applicable.

#### ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 21, 2007

## BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

## BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

# **BVF INVESTMENTS, L.L.C.**

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

# INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its attorney-in-fact

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

# **BVF PARTNERS L.P.**

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

### **BVF INC.**

By: /s/ MARK N. LAMPERT

#### AGREEMENT REGARDING JOINT FILING

The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Investments, L.L.C., a Delaware limited liability company, Investment 10, L.L.C., an Illinois limited liability company, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the information required by Schedule 13G, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.

Dated: November 21, 2007

#### BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

#### BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

## **BVF INVESTMENTS, L.L.C.**

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

# INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its attorney-in-fact

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

## **BVF PARTNERS L.P.**

By: BVF Inc., its general partner

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

# **BVF INC.**

By: /s/ MARK N. LAMPERT

Mark N. Lampert President